Pfenex Inc (PFNX) Lowered to Strong Sell at ValuEngine
ValuEngine lowered shares of Pfenex Inc (NYSEMKT:PFNX) from a sell rating to a strong sell rating in a research note issued to investors on Friday morning.
Several other analysts have also recently issued reports on PFNX. Zacks Investment Research raised shares of Pfenex from a strong sell rating to a hold rating in a research report on Saturday, August 26th. William Blair reissued an outperform rating on shares of Pfenex in a research report on Thursday, August 10th.
Pfenex (NYSEMKT PFNX) traded down 2.49% on Friday, reaching $3.52. 30,916 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $4.03 and a 200-day moving average of $4.95. The stock has a market cap of $82.82 million, a price-to-earnings ratio of 56.77 and a beta of 4.65. Pfenex has a one year low of $3.16 and a one year high of $11.35.
Pfenex (NYSEMKT:PFNX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.06. The business had revenue of $3.03 million for the quarter, compared to analyst estimates of $3.10 million. Pfenex had a negative return on equity of 75.61% and a negative net margin of 406.87%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.43) EPS. Equities research analysts forecast that Pfenex will post ($2.09) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/pfenex-inc-pfnx-lowered-to-strong-sell-at-valuengine/1538452.html.
In other Pfenex news, Director Jason Grenfell-Gardner purchased 10,000 shares of Pfenex stock in a transaction dated Monday, June 12th. The shares were acquired at an average price of $4.51 per share, with a total value of $45,100.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at $45,100. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
A number of hedge funds have recently modified their holdings of PFNX. Russell Investments Group Ltd. boosted its stake in shares of Pfenex by 221.0% in the first quarter. Russell Investments Group Ltd. now owns 32,186 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 22,160 shares during the period. Algert Global LLC boosted its stake in shares of Pfenex by 207.3% in the first quarter. Algert Global LLC now owns 34,603 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 23,344 shares during the period. Nine Chapters Capital Management LLC purchased a new stake in shares of Pfenex during the first quarter valued at $265,000. Goldman Sachs Group Inc. boosted its stake in shares of Pfenex by 126.7% in the first quarter. Goldman Sachs Group Inc. now owns 56,020 shares of the biotechnology company’s stock valued at $325,000 after buying an additional 31,308 shares during the period. Finally, LMR Partners LLP purchased a new stake in shares of Pfenex during the second quarter valued at $252,000.
Pfenex Company Profile
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.